Serum Endostatin Is a Novel Marker for COPD Associated with Lower Lung Function, Exacerbation and Systemic Inflammation

• Published in: International journal of chronic obstructive pulmonary disease Vol. 15; pp. 397 - 407
• Main Authors: Wu, Yanqiu, Qin, Jiangyue, He, Junyun, Shen, Yongchun, Wang, Hao, Li, Yanping, Zeng, Qianglin, Dong, Jiajia, An, Yunfei, Xiong, Shuguang, Feng, Mei, Wen, Fuqiang
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.02.2020; Dove Medical Press Ltd; Dove; Dove Medical Press
• Subjects: Adult; Aged; Airway management; angiogenesis; Angiogenesis inhibitors; Biomarkers; Biomarkers - blood; Body mass index; C-reactive protein; C-Reactive Protein - analysis; Chronic obstructive lung disease; Chronic obstructive pulmonary disease; Collagen Type VIII - blood; Cross-Sectional Studies; Development and progression; Diabetic retinopathy; Disease Progression; Diseases; endostatin; Endostatins - blood; Endothelial growth factors; Endothelium; Female; Forced Expiratory Volume; Humans; Inflammation; Inflammation Mediators - blood; Inflammatory diseases; Lung - physiopathology; Lung diseases; lung function; Male; Middle Aged; Original Research; Predictive Value of Tests; Prognosis; Proteins; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary function tests; Retrospective Studies; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - blood; Vital Capacity; China; United States > US; lung function; endostatin; inflammation; angiogenesis; chronic obstructive pulmonary disease
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S234760

It is well known that angiogenesis contributes to the progression of chronic obstructive pulmonary disease (COPD) by initiating the remodeling of bronchial vasculature. However, the specific molecular mechanisms are incompletely understood. This research aimed to explore whether endostatin, a member of endogenous antiangiogenic proteins, is a biomarker in COPD and plays a role in the angiogenesis of COPD. 100 stable COPD patients, 130 patients with acute exacerbation (AECOPD) and 68 healthy volunteers were recruited in this research. Lung function test was conducted in the healthy people and stable COPD patients. Serum endostatin, C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) of all the subjects were measured by Human Magnetic Luminex Screening Assay. Serum endostatin level was significantly higher in stable COPD compared with healthy control and even more in AECOPD patients (P<0.001). Besides, stable COPD patients with frequent exacerbation (≥2 exacerbations per year) in the last 1 year had a higher concentration of endostatin in the circulation compared to the patients with less exacerbation (P=0.037). Furthermore, circulatory endostatin was negatively associated with forced expiratory volume in 1 s % predicted (FEV %pre), an index of lung function in the stable COPD group (P=0.009). Finally, endostatin was positively correlated to serum CRP in COPD group (including stable and AECOPD) (P=0.005) and all the subjects (P<0.001), but only associated with VEGF in the total participants (P=0.002), not in the COPD group. These results suggested that endostatin is a biomarker for COPD and associated with lower lung function, exacerbation, and systemic inflammation. Endostatin potentially contributes to the pathogenesis of COPD.